Clinical trials: Neoplams
Non Small Cell Lung Cancer
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
The purpose of this study is to determine whether Eribulin Mesylate Administered in Combination with Pemetrexed is safe and tolerable and to gain a preliminary indication of clinical benefit when administered to Patients with…
- Trial name
- NCT01126736
- Testing
- eribulin mesylate, pemetrexed, Eribulin mesylate (eribulin; E7389)
- Where
- 18 sites in United States, Czechia and 3 more
- Volunteers
- 98 people
- Sponsor
- Eisai Inc.